Breaking Biodefense News: Aethlon Medical (NASDAQ:OTCQB:
AEMD) Receives Notice of DARPA Contract Renewal
SAN DIEGO - September 22, 2014 (Investorideas.com newswire)
Aethlon Medical, Inc. (NASDAQ:OTCBB:AEMD), the pioneer in developing targeted therapeutic
devices to address infectious disease, cancer and other life-threatening
conditions, disclosed today that the Defense Advanced Research Projects Agency
(DARPA) has informed the Company that it plans to exercise an option to proceed
with year four of a five-year $5.9 million contract that was awarded to Aethlon
on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.
The
fourth year of Aethlon's DLT contract contains three milestones representing a
potential of $669,292 in revenue opportunity. To date, Aethlon has invoiced
$4,252,037 to DARPA for achieving twenty of twenty-three milestone objectives
targeted in the first three years of the DLT program.
The goal
of the Dialysis-Like Therapeutics (DLT) program is to develop a portable device
that removes "dirty" blood from the body, separates harmful agents,
and returns "clean" blood to the body in a manner similar to dialysis
treatment of kidney failure. The resulting device could decrease the morbidity
and mortality of sepsis, thereby saving thousands of lives and billions of
dollars in the United States annually.
To do so,
the DLT program seeks to develop multiple component technologies, integrate
them into a portable device, and rigorously validate device effectiveness. Key
technical areas and representative technical approaches include:
·
Persistent
interrogation of the entire blood volume via sensing technologies such as
surface enhanced Raman spectroscopy (SERS). This capability may enable early
identification of bacteria, viruses, toxins, and cytokines.
·
High-flow
fluid manipulation without the use of anticoagulants via novel
biocompatible/biomimetic architectures and advanced surface functionalization
chemistries.
·
Continuous
removal of pathogens, toxins, activated cells, exosomes, and cytokines via a
diverse suite of "label-free" technologies such as synthetic mannose
binding lectins and selective adsorption cartridges.
·
Closed-loop
therapy with system feedback to monitor and redirect patient state based on
conditional probability and reduced order techniques.
The
integration and validation of these component technologies focuses on
establishing a path to FDA Investigational Device Exemption (IDE) before the
completion of the program. From there, the device will be available for
transition to military medical commands and clinical trials required for final
regulatory approval.
In
addition to treating sepsis, the DLT device represents a flexible platform that
may be configured to combat engineered and evolving pathogens.
Read
this release in full at: http://www.investorideas.com/CO/AEMD/news/2014/09222.asp
About Aethlon Medical
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®,
a first-in-class device that selectively targets the rapid elimination of
circulating viruses and tumor-secreted exosomes that promote cancer
progression. Exosome Sciences, Inc. is a majority owned subsidiary that is
advancing exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. Additional information can be found online
at www.AethlonMedical.com
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Jim
Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher
of news and research as well as creates original content as a news source.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Investorideas is a news source on Google news and
Linkedintoday plus hundreds of syndication partners. Our site does not make
recommendations for purchases or sale of stocks or products. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: AEMD
subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer : Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, mining stocks, oil and gas stocks and more...
No comments:
Post a Comment